vs
Side-by-side financial comparison of Affinity Bancshares, Inc. (AFBI) and Sunshine Biopharma Inc. (SBFM). Click either name above to swap in a different company.
Sunshine Biopharma Inc. is the larger business by last-quarter revenue ($8.6M vs $8.6M, roughly 1.0× Affinity Bancshares, Inc.). Affinity Bancshares, Inc. runs the higher net margin — 24.9% vs -25.0%, a 49.8% gap on every dollar of revenue. On growth, Affinity Bancshares, Inc. posted the faster year-over-year revenue change (12.8% vs -10.6%). Affinity Bancshares, Inc. produced more free cash flow last quarter ($11.2M vs $-1.6M). Over the past eight quarters, Affinity Bancshares, Inc.'s revenue compounded faster (8.1% CAGR vs 6.6%).
Sunshine Biopharma Inc. is a clinical-stage biopharmaceutical company focused on researching, developing and commercializing innovative therapies for oncology, neurodegenerative disorders and infectious diseases. It targets unmet medical needs across global markets, with a pipeline of targeted therapeutic candidates designed to improve patient treatment outcomes.
AFBI vs SBFM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.6M | $8.6M |
| Net Profit | $2.1M | $-2.1M |
| Gross Margin | — | 35.3% |
| Operating Margin | 35.9% | -20.9% |
| Net Margin | 24.9% | -25.0% |
| Revenue YoY | 12.8% | -10.6% |
| Net Profit YoY | 58.5% | 0.8% |
| EPS (diluted) | $0.34 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.6M | $8.6M | ||
| Q3 25 | $8.4M | $9.4M | ||
| Q2 25 | $8.3M | $9.4M | ||
| Q1 25 | $7.8M | $8.9M | ||
| Q4 24 | $7.6M | $9.6M | ||
| Q3 24 | $8.0M | $8.4M | ||
| Q2 24 | $8.3M | $9.3M | ||
| Q1 24 | $7.3M | $7.5M |
| Q4 25 | $2.1M | $-2.1M | ||
| Q3 25 | $2.2M | $-883.8K | ||
| Q2 25 | $2.2M | $-1.8M | ||
| Q1 25 | $1.8M | $-1.2M | ||
| Q4 24 | $1.3M | $-2.2M | ||
| Q3 24 | $1.7M | $-1.2M | ||
| Q2 24 | $1.0M | $-494.3K | ||
| Q1 24 | $1.3M | $-1.3M |
| Q4 25 | — | 35.3% | ||
| Q3 25 | — | 32.6% | ||
| Q2 25 | — | 36.4% | ||
| Q1 25 | — | 30.7% | ||
| Q4 24 | — | 32.2% | ||
| Q3 24 | — | 34.0% | ||
| Q2 24 | — | 25.3% | ||
| Q1 24 | — | 31.2% |
| Q4 25 | 35.9% | -20.9% | ||
| Q3 25 | 34.9% | -11.5% | ||
| Q2 25 | 34.1% | -21.8% | ||
| Q1 25 | 30.8% | -14.6% | ||
| Q4 24 | 21.1% | -21.7% | ||
| Q3 24 | 28.5% | -13.1% | ||
| Q2 24 | 16.2% | -13.6% | ||
| Q1 24 | 24.0% | -17.9% |
| Q4 25 | 24.9% | -25.0% | ||
| Q3 25 | 26.5% | -9.4% | ||
| Q2 25 | 25.9% | -18.8% | ||
| Q1 25 | 23.4% | -13.3% | ||
| Q4 24 | 17.7% | -22.5% | ||
| Q3 24 | 21.7% | -14.2% | ||
| Q2 24 | 12.5% | -5.3% | ||
| Q1 24 | 18.2% | -17.0% |
| Q4 25 | $0.34 | — | ||
| Q3 25 | $0.34 | $-0.54 | ||
| Q2 25 | $0.33 | $-0.82 | ||
| Q1 25 | $0.28 | $-0.44 | ||
| Q4 24 | $0.21 | $49.77 | ||
| Q3 24 | $0.26 | $-11.61 | ||
| Q2 24 | $0.16 | $-43.48 | ||
| Q1 24 | $0.20 | $-2.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $127.0M | $23.0M |
| Total Assets | $881.7M | $30.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.9M | — | ||
| Q3 25 | $84.8M | — | ||
| Q2 25 | $89.7M | — | ||
| Q1 25 | $74.7M | — | ||
| Q4 24 | $41.4M | — | ||
| Q3 24 | $52.3M | — | ||
| Q2 24 | $50.4M | — | ||
| Q1 24 | $61.4M | — |
| Q4 25 | $127.0M | $23.0M | ||
| Q3 25 | $125.4M | $24.2M | ||
| Q2 25 | $124.1M | $25.7M | ||
| Q1 25 | $122.3M | $22.7M | ||
| Q4 24 | $129.1M | $23.5M | ||
| Q3 24 | $128.4M | $25.0M | ||
| Q2 24 | $125.1M | $23.5M | ||
| Q1 24 | $123.3M | $24.8M |
| Q4 25 | $881.7M | $30.1M | ||
| Q3 25 | $925.2M | $31.5M | ||
| Q2 25 | $933.8M | $32.0M | ||
| Q1 25 | $912.5M | $29.2M | ||
| Q4 24 | $866.8M | $30.6M | ||
| Q3 24 | $878.6M | $30.1M | ||
| Q2 24 | $873.6M | $29.3M | ||
| Q1 24 | $869.5M | $31.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.6M | $-1.6M |
| Free Cash FlowOCF − Capex | $11.2M | $-1.6M |
| FCF MarginFCF / Revenue | 130.9% | -18.9% |
| Capex IntensityCapex / Revenue | 4.9% | 0.0% |
| Cash ConversionOCF / Net Profit | 5.46× | — |
| TTM Free Cash FlowTrailing 4 quarters | $20.3M | $-5.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | $-1.6M | ||
| Q3 25 | $3.7M | $-727.8K | ||
| Q2 25 | $3.8M | $-1.3M | ||
| Q1 25 | $1.9M | $-1.7M | ||
| Q4 24 | $6.8M | $-3.4M | ||
| Q3 24 | $4.1M | $-1.4M | ||
| Q2 24 | $619.0K | $-4.6M | ||
| Q1 24 | $1.2M | $-3.2M |
| Q4 25 | $11.2M | $-1.6M | ||
| Q3 25 | $3.6M | $-735.8K | ||
| Q2 25 | $3.7M | $-1.4M | ||
| Q1 25 | $1.8M | $-1.7M | ||
| Q4 24 | $6.4M | $-3.5M | ||
| Q3 24 | $4.0M | $-1.9M | ||
| Q2 24 | $489.0K | $-5.6M | ||
| Q1 24 | $1.1M | $-3.2M |
| Q4 25 | 130.9% | -18.9% | ||
| Q3 25 | 43.3% | -7.8% | ||
| Q2 25 | 44.0% | -15.2% | ||
| Q1 25 | 22.7% | -19.3% | ||
| Q4 24 | 83.9% | -36.6% | ||
| Q3 24 | 49.5% | -22.2% | ||
| Q2 24 | 5.9% | -59.7% | ||
| Q1 24 | 14.8% | -43.1% |
| Q4 25 | 4.9% | 0.0% | ||
| Q3 25 | 0.8% | 0.1% | ||
| Q2 25 | 1.4% | 1.7% | ||
| Q1 25 | 1.9% | 0.1% | ||
| Q4 24 | 5.6% | 1.1% | ||
| Q3 24 | 1.7% | 6.1% | ||
| Q2 24 | 1.6% | 10.5% | ||
| Q1 24 | 1.8% | 0.8% |
| Q4 25 | 5.46× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 1.75× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 5.05× | — | ||
| Q3 24 | 2.36× | — | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 0.91× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
